Mark Christopher, None;
James Proudfoot, None;
Christopher Bowd, None;
Akram Belghith, None;
Michael Goldbaum, None;
Jasmin Rezapour, None;
Sasan Moghimi, None;
Robert Weinreb, Aerie Pharmaceuticals (C), Allergan (C), Bausch & Lomb (C), Bausch & Lomb (F), Carl Zeiss Meditec (F), Carl Zeiss Meditec (P), Centervue (F), Eyenovia (C), Heidelberg Engineering (F), Konan Medical (F), Optovue (F), Toromedes (P);
Massimo Fazio, EyeSight Foundation of Alabama (F), Heidelberg Engineering (F), National Eye Institute (F), Research to Prevent Blindess (F);
Christopher Girkin, EyeSight Foundation of Alabama (F), Heidelberg Engineering (F), National Eye Institute (F), Research to Prevent Blindess (F);
Carlos De Moraes, Belite (C), Carl Zeiss Meditec (C), Galimedix (C), Heidelberg Engineering (R), Novartis (C), Perfuse Therapeutics (C), Reichert (C), Topcon (R);
Jeffrey Liebmann, Aerie Pharmaceuticals (C), Alcon (C), Allergan (C), Bausch & Lomb (C), Bausch & Lomb (F), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Eyenovia (C), Galimedix (C), Heidelberg Engineering (C), Heidelberg Engineering (F), National Eye Institute (F), Novartis (F), Optovue (F), Recihert (F), Reichert (F), Research to Prevent Blindness (F), Topcon (F);
Linda Zangwill, Carl Zeiss Meditec (F), Carl Zeiss Meditec (P), Heidelberg Engineering (F), Heidelberg Engineering (R), National Eye Institute (F), Optovue (F), Topcon (F)